These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
937 related articles for article (PubMed ID: 7640209)
81. Expression of multidrug resistance protein-related genes in lung cancer: correlation with drug response. Young LC; Campling BG; Voskoglou-Nomikos T; Cole SP; Deeley RG; Gerlach JH Clin Cancer Res; 1999 Mar; 5(3):673-80. PubMed ID: 10100721 [TBL] [Abstract][Full Text] [Related]
82. Double-edged sword of chemosensitizer: increase of multidrug resistance protein (MRP) in leukemic cells by an MRP inhibitor probenecid. Kim HS; Min YD; Choi CH Biochem Biophys Res Commun; 2001 Apr; 283(1):64-71. PubMed ID: 11322768 [TBL] [Abstract][Full Text] [Related]
83. Emergence of different mechanisms of resistance in the evolution of multidrug resistance in murine erythroleukemia cell lines. Modrak DE; Draper MP; Levy SB Biochem Pharmacol; 1997 Dec; 54(12):1297-306. PubMed ID: 9393672 [TBL] [Abstract][Full Text] [Related]
84. Cellular determinants of resistance to indolocarbazole analogue 6-N-formylamino-12,13-dihydro-1,11-dihydroxy-13(beta-D-glucopyranosyl)- 5H-indolo[2,3-alpha]pyrrolo[3,4-c]carbazole-5,7(6H)-dione (NB-506), a novel potent topoisomerase I inhibitor, in multidrug-resistant human tumor cells. Vanhoefer U; Voigt W; Hilger RA; Yin MB; Harstrick A; Seeber S; Rustum YM Oncol Res; 1997; 9(9):485-94. PubMed ID: 9495454 [TBL] [Abstract][Full Text] [Related]
85. p53 may mediate the mdr-1 expression via the WT1 gene in human vincristine-resistant leukemia/lymphoma cell lines. Hirose M; Kuroda Y Cancer Lett; 1998 Jul; 129(2):165-71. PubMed ID: 9719458 [TBL] [Abstract][Full Text] [Related]
86. Lack of elevated drug efflux in adriamycin-resistant immunoblastic B lymphoma cells with mdr1 overexpression. Chao CC FEBS Lett; 1995 Oct; 373(3):285-90. PubMed ID: 7589484 [TBL] [Abstract][Full Text] [Related]
87. In vivo etoposide-resistant C6 glioma cell line: significance of altered DNA topoisomerase II activity in multi-drug resistance. Taki T; Ohnishi T; Arita N; Hiraga S; Hayakawa T J Neurooncol; 1998 Jan; 36(1):41-53. PubMed ID: 9525824 [TBL] [Abstract][Full Text] [Related]
88. Energy-dependent processes involved in reduced drug accumulation in multidrug-resistant human lung cancer cell lines without P-glycoprotein expression. Versantvoort CH; Broxterman HJ; Pinedo HM; de Vries EG; Feller N; Kuiper CM; Lankelma J Cancer Res; 1992 Jan; 52(1):17-23. PubMed ID: 1309222 [TBL] [Abstract][Full Text] [Related]
89. A novel bioassay for P-glycoprotein functionality using cytochalasin D. Elbling L; Berger W; Weiss RM; Printz D; Fritsch G; Micksche M Cytometry; 1998 Mar; 31(3):187-98. PubMed ID: 9515718 [TBL] [Abstract][Full Text] [Related]
91. [Reversion of multidrug resistance in vitro of lung adenocarcinoma by mdr1 ribozyme]. Chen L; Liu Y Zhonghua Zhong Liu Za Zhi; 2000 May; 22(3):189-91. PubMed ID: 11778227 [TBL] [Abstract][Full Text] [Related]
93. Expression of multidrug resistance-associated protein (MRP) mRNA in blast cells from acute myeloid leukemia (AML) patients. Ross DD; Doyle LA; Schiffer CA; Lee EJ; Grant CE; Cole SP; Deeley RG; Yang W; Tong Y Leukemia; 1996 Jan; 10(1):48-55. PubMed ID: 8558937 [TBL] [Abstract][Full Text] [Related]
94. Involvement of the multidrug resistance protein 3 in drug sensitivity and its expression in human glioma. Haga S; Hinoshita E; Ikezaki K; Fukui M; Scheffer GL; Uchiumi T; Kuwano M Jpn J Cancer Res; 2001 Feb; 92(2):211-9. PubMed ID: 11223551 [TBL] [Abstract][Full Text] [Related]
95. Cross-resistance to antifolates in multidrug resistant cell lines with P-glycoprotein or multidrug resistance protein expression. van Triest B; Pinedo HM; Telleman F; van der Wilt CL; Jansen G; Peters GJ Biochem Pharmacol; 1997 Jun; 53(12):1855-66. PubMed ID: 9256160 [TBL] [Abstract][Full Text] [Related]
96. Increased rate of adenosine triphosphate-dependent etoposide (VP-16) efflux in a murine leukemia cell line overexpressing the multidrug resistance-associated protein (MRP) gene. Lorico A; Rappa G; Srimatkandada S; Catapano CV; Fernandes DJ; Germino JF; Sartorelli AC Cancer Res; 1995 Oct; 55(19):4352-60. PubMed ID: 7671247 [TBL] [Abstract][Full Text] [Related]
97. Expression of mdr1, mrp, topoisomerase II alpha/beta, and cyclin A in primary or relapsed states of acute lymphoblastic leukaemias. Beck J; Handgretinger R; Dopfer R; Klingebiel T; Niethammer D; Gekeler V Br J Haematol; 1995 Feb; 89(2):356-63. PubMed ID: 7873386 [TBL] [Abstract][Full Text] [Related]
98. Differential cytotoxicity of 19 anticancer agents in wild type and etoposide resistant small cell lung cancer cell lines. Jensen PB; Christensen IJ; Sehested M; Hansen HH; Vindeløv L Br J Cancer; 1993 Feb; 67(2):311-20. PubMed ID: 8094293 [TBL] [Abstract][Full Text] [Related]
99. Pharmacological characterization of multidrug resistant MRP-transfected human tumor cells. Cole SP; Sparks KE; Fraser K; Loe DW; Grant CE; Wilson GM; Deeley RG Cancer Res; 1994 Nov; 54(22):5902-10. PubMed ID: 7954421 [TBL] [Abstract][Full Text] [Related]
100. Development of novel reversal agents, imidazothiazole derivatives, targeting MDR1- and MRP-mediated multidrug resistance. Naito S; Koike K; Ono M; Machida T; Tasaka S; Kiue A; Koga H; Kumazawa J Oncol Res; 1998; 10(3):123-32. PubMed ID: 9700723 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]